AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03027531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eKISS: electronic KIOSK for Safer-Sex
Description: An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
Study NCT02832973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone 25 mg
Study NCT02832973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide,
Description: Furosemide 20-40 mg
Study NCT02832973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride 5 mg
Study NCT02832973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 5-10 mg
Study NCT02832973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol 5-10 mg
Study NCT03448068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated.
Study NCT03448068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care
Study NCT02326454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: talaporfin sodium
Description: 1 mg/kg
Study NCT02326454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02326454 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Drug Activator 100 J/cm
Description: Light Dose: 100 J/cm
Study NCT02326454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Activator 100 J/cm
Description: Light Dose: 100 J/cm
Study NCT02326454 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Drug Activator 200 J/cm
Description: Light Dose: 200 J/cm
Study NCT02326454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Activator 200 J/cm
Description: Light Dose: 200 J/cm
Study NCT03893968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information by an assistant nurse
Description: Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by an assistent nurse.
Study NCT03893968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information by a doctor
Description: Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by a doctor.
Study NCT01888640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS Parameters: Active TENS and Placebo TENS~* TENS Frequency - 2-125 Hz~* TENS Pulse Width - 200 µs~* TENS Intensity - Maximal tolerable intensity~* Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~* Administration - Daily~* TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care
Study NCT01888640 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: TENS Parameters: Active TENS and Placebo TENS~* TENS Frequency - 2-125 Hz~* TENS Pulse Width - 200 µs~* TENS Intensity - Maximal tolerable intensity~* Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~* Administration - Daily~* TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care
Study NCT03669458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below the Knee peripheral intervention
Description: Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone
Study NCT01342835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
Study NCT01227044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
Study NCT01227044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Medication Management/Medication Coaching
Description: Placebo + Medication Management/Medication Coaching
Study NCT02250274 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: LAIV
Description: Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.
Study NCT02250274 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IIV
Description: A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.~\[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.\]
Study NCT00473343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix® cream
Study NCT03121404 — intervention group
Intervention type: PROCEDURE
Intervention: Rectus abdominis muscle biopsy
Description: Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
Study NCT03256500 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
Study NCT03256500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
Study NCT01079897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atopiclair
Description: topical applied cream, twice daily
Study NCT01079897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EHK02-01
Description: topical applied cream containing 7% ectoine
Study NCT03518593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash and counselling
Description: Additional 500 Ksh per child per month and household visits by Community health Volunteers (CHVs)
Study NCT02755311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver resection
Description: Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.
Study NCT02755311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transarterial chemoembolization
Description: A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
Study NCT02755311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
Study NCT02755311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipiodol
Description: Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
Study NCT02755311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil
Description: The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.
Study NCT02755311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: absorbable gelatin sponge particles
Description: Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
Study NCT03891264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
Study NCT01446406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MONARCA
Description: Monitoring affective symptoms entered by the patient every day.
Study NCT01446406 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NON-MONARCA
Description: A mobile phone for communication purposes only. No application has been installed.
Study NCT00574275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
Study NCT00574275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
Study NCT00574275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
Study NCT00574275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
Study NCT00644774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: 2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
Study NCT00644774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: 2.5 ml of cherry flavored oral suspension 100 mg/5 ml
Study NCT01169155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoke Alarm Stimuli
Description: See arm descriptions for information about the smoke alarm stimuli interventions.
Study NCT01620242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25 mg/m2 every 3 weeks by IV administration
Study NCT04170322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thin pvc gastric tube
Description: a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon
Study NCT04170322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thick silicone gastric tube
Description: a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
Study NCT03496428 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dental implant impressions- Different Techniques
Description: Assessment of soft tissues changes with different techniques
Study NCT00343889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HB-PRP~T vaccine + OPV
Description: 0.5 mL, Intramuscular
Study NCT00343889 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB/Hib™ + OPV vaccine
Description: 0.5 mL, Intramuscular
Study NCT00343889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine
Description: Oral co-administered with study vaccine
Study NCT00343889 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Polio Vaccine
Description: Oral co-administered with study vaccine
Study NCT04276428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC.
Study NCT04276428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC.
Study NCT00492752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
Study NCT00492752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (orally) twice daily
Study NCT02691442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75%
Description: The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
Study NCT02691442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.5%
Description: The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
Study NCT02691442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.5% + epinephrin 1/200000
Description: The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
Study NCT03290833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic
Description: Participants will be placed in the robot and practice common hand tasks involving single finger range of motion exercise, grasping, and pinching objects.
Study NCT03290833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
Study NCT03290833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
Study NCT04514523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QBSAfe Toolkit
Description: The QBSAfe toolkit focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety.
Study NCT03446950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Surgery
Description: Patients will undergo elective surgery on vagina or bladder
Study NCT03275194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Following complete cytoreductive surgery without any evidence of residual disease, the patient will be randomized either HIPEC (intervention) or no-HIPEC (control) in the operative Room. If the arm HIPEC is obtained, then a HIPEC procedure with cisplatin and doxorubicin will be performed. If no-HIPEC (control arm) is assigned then the surgical procedure will be finished.
Study NCT02260115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LABS™
Description: hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
Study NCT02260115 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Surgical Control
Description: Surgery only
Study NCT04161430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108; Placebo matching sitagliptin
Description: Phase A (Weeks 1-24): DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks.
Study NCT04161430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching DBPR108; Sitagliptin; DBPR108
Description: Phase A (Weeks 1-24): Placebo matching DBPR108 100mg once daily under fasted conditions for 24 weeks; Sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks.
Study NCT04161430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108
Description: Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks.
Study NCT02331082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Quality Improvement
Description: For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
Study NCT02331082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic Care Model
Description: Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.